Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| TKL Research, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| topical cream acyclovir/hydrocortisone | Experimental | topical cream acyclovir/hydrocortisone used |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| acyclovir/hydrocortisone cream | Drug | cream applied topically to lesion five times daily for five days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reporting of Adverse Events | treatment period is for 5 days and follow up visits at 7days and 21 days after first dose | day 1 to day 21 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Ginsburg, D.O. | Meda Pharma US | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MCS Clinical Trials | Los Angeles | California | 90057 | United States | ||
| Sunshine Research Center |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Topical Cream | commercial product being used acyclovir/hydrocortisone cream: cream applied topically to lesion five times daily for five days |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Opa-locka |
| Florida |
| 33054 |
| United States |
| Altus Rsearch,INC | West Palm Beach | Florida | 33407 | United States |
| Provident Clincal Research | Addison | Illinois | 60101 | United States |
| Central Kentucky Research | Lexington | Kentucky | 40509 | United States |
| Rochester Clinical Research | Rochester | New York | 14609 | United States |
| PGM Research of Winston-Salem, LLC | Winston-Salem | North Carolina | 27103 | United States |
| Clinical Partners LLC | Johnston | Rhode Island | 02919 | United States |
| Corsicana Medical Research,PNC | Corsicana | Texas | 75110 | United States |
| National Clinical Research-Richmond,Inc. | Richmond | Virginia | 23294 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Topical Cream | xerese topical cream is the only active used in this trial |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Categorical | Count of Participants | Participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
| |||||||||||||||||||||||
| age of subjects with prior history of herpes labialis outbreak | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Reporting of Adverse Events | treatment period is for 5 days and follow up visits at 7days and 21 days after first dose | Posted | Number | participants | day 1 to day 21 |
|
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Topical Cream | commercial product being used acyclovir/hydrocortisone cream: cream applied topically to lesion five times daily for five days | 0 | 54 | 9 | 54 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| general disorder | General disorders | Systematic Assessment |
| ||
| URI | Infections and infestations | Systematic Assessment |
| ||
| lip injury | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| paresthesia oral | Gastrointestinal disorders | Systematic Assessment |
| ||
| rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| headache | Nervous system disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| David Ginsberg, DO | Meda Pharmaceutical | 732 564 2200 | ginsberg.david@gmail.com |
| ID | Term |
|---|---|
| D006560 | Herpes Labialis |
| ID | Term |
|---|---|
| D006561 | Herpes Simplex |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D017193 | Skin Diseases, Viral |
| D008047 | Lip Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000212 | Acyclovir |
| ID | Term |
|---|---|
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| >=65 years |
|
| age 7 to 9 years |
|